surmount-1 tirzepatide weight loss percent 72 weeks for Obesity Treatment and Diabetes Prevention Lilly released results for SURMOUNT-2,

Choose Retatrutide If: Maximum weight loss is the primary goal Previous GLP-1 agonists produced significant nausea (GIP component may help) No specific liver health concerns requiring treatment Tolerance for slightly higher GI side effects during titration Response to dual agonists (like tirzepatide) has been positive Choose Survodutide If: Liver health concerns exist (fatty liver, MASH, elevated liver enzymes) Moderate weight loss goals rather than maximum efficacy priority Interest in potential cardiovascular outcome benefits (CVOT data pending) Preference for a compound with FDA Breakthrough Therapy designation Plans to potentially transition to approved medication once available For most people focused primarily on weight loss, Retatrutide presents the stronger option based on available data

The digestive system finds its new normal

The reason is that tesofensine increases norepinephrine and dopamine signaling, which can disrupt sleep if peak signaling lands during the evening

3b and 4f), further suggesting a reduction in de novo lipogenesis in the liver

Semaglutide should not be used if you or your family has a history of certain thyroid tumors or Multiple Endocrine Neoplasia type 2 syndrome